Abstract
Oxidative stress and inflammation play a major role in the progression of renal damage and antioxidants are potentially useful therapeutic options in chronic renal disease. We investigated if treatment with tempol, a superoxide dismutase mimetic that has beneficial effects in several experimental models of hypertension and acute kidney injury, ameliorates the chronic renal damage resulting in renal mass reduction. Rats with surgical 5/6 nephrectomy were randomly assigned to receive no treatment (CRF group, n = 10) or tempol, 1 mmol/l in the drinking water (CRF-tempol group, n = 10). Sham-operated rats (n = 10) served as controls. All rats were followed for 12 weeks post-nephrectomy. Tempol treatment reduced plasma malondialdehyde (MDA) levels and halved the number of superoxide-positive cells in the remnant kidney; however, the number of hydrogen peroxide-positive cells increased and the overall renal oxidative stress (MDA and nitrotyrosine abundance) and inflammation (interstitial p65 NF-κB, macrophage and lymphocyte infiltration) were unchanged. Proteinuria, renal function and glomerular and tubulointerstitial damage in the remnant kidney were similar in the CRF and CRF-tempol groups. In conclusion, tempol administration, at the dose used in these studies, decreased plasma MDA and heightened superoxide dismutation in the kidney, but was incapable of reducing renal oxidative stress or improving renal function or structure in the remnant kidney model.
Journal Section:
Original Paper
References
1.
Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, Warnock DG, Vinicor F: Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57:1–6.
2.
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001;12:1315–1325.
[PubMed]
3.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
[PubMed]
4.
Vaziri ND: Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004;24:469–473.
[PubMed]
5.
Vaziri ND, Rodriguez-Iturbe B: Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2007;2:582–593.
6.
Vaziri ND, Bai Y, Ni Z, Quiroz Y, Rodriguez-Iturbe B: Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007;323:85–93.
[PubMed]
7.
Sindhu RK, Ehdaie A, Farmand F, Dhaliwal KK, Nguyen T, Zhan CD, Roberts CK, Vaziri ND: Expression of catalase and glutathione peroxidase in renal insufficiency. Biochim Biophys Acta 2005;1743:86–92.
[PubMed]
8.
Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709–720.
[PubMed]
9.
Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E: Mycophenolate mofetil prevents the progression of renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945–955.
[PubMed]
10.
Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54:1510–1519.
[PubMed]
11.
Fujihara CK, Antunes GR, Mattar AL, Malheiros DM, Vieira JM Jr, Zatz R: Chronic inhibition of nuclear factor-κB attenuates renal injury in the 5/6 renal ablation model. Am J Physiol Renal Physiol 2007;292:F92–F99.
[PubMed]
12.
Tain YL, Freshour G, Dikalova A, Griendling K, Baylis C: Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 2007;292:F1404–F1410.
[PubMed]
13.
Quiroz Y, Romero F, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B: Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression in rats with renal mass reduction. Am J Physiol, Renal Physiol 2008;294:F336–F344.
[PubMed]
14.
Vaziri ND, Oveisi F, Reyes GA, Zhou XJ: Dysregulation of melatonin metabolism in chronic renal insufficiency: role of erythropoietin-deficiency anemia. Kidney Int 1996;50:653–656.
[PubMed]
15.
Soule BP, Hyodo F, Matsumoto KI, Simone NL, Cook JA, Krishna MC, Mitchell JB: The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007;42:1632–1650.
[PubMed]
16.
Schnackenberg CG, Wilcox CS: Two-week administration of tempol attenuates both hypertension and renal excretion of 8-isoprostaglandin F2α. Hypertension 1999;33:424–428.
[PubMed]
17.
Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y: The SOD-mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 2004;15:306–415.
[PubMed]
18.
Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781– 786.
[PubMed]
19.
Vaziri ND, Ding Y, Ni Z: Compensatory upregulation of NO synthase isoforms in lead-induced hypertension: reversal by an SOD-mimetic drug. J Pharmacol Exp Ther 2001;298:679–685.
[PubMed]
20.
Guron GS, Grimberg ES, Basu S, Herlitz H: Acute effects of the superoxide dismutase mimetic tempol on split kidney function in two-kidney one-clip hypertensive rats. J Hypertens 2006;24:387–394.
[PubMed]
21.
Leach M, Frank S, Olbrich A, Pfeilschifter J, Thiemermann C: Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: effects of the superoxide anion radical scavenger, tempol, on organ injury. Br J Pharmacol 1998;125:817–825.
[PubMed]
22.
Mota-Filipe H, McDonald MC, Cuzzocrea S, Thiemermann C: A membrane-permeable radical scavenger reduces the organ injury in hemorrhagic shock. Shock 1999;12:255–261.
[PubMed]
23.
Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, Thiemermann C: Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 2000;58:658–673.
[PubMed]
24.
Asaba K, Tojo A, Onozato ML, Goto A, Fujita T: Double-edged action of SOD mimetic in diabetic nephropathy. J Cardiovasc Pharmacol 2007;49:13–19.
[PubMed]
25.
Vaziri ND, Dicus M, Ho N, Sindhu R: Oxidative stress and dysregulation of superoxide dismutase and NAD(P)H oxidase in renal insufficiency. Kidney Int 2003;63:179–185.
[PubMed]
26.
Linares E, Giorgio S, Augusto O: Inhibition of in vivo leishmanicidal mechanisms by tempol: nitric oxide down-regulation and oxidant scavenging. Free Radic Biol Med 2008;44:1668–1676.
[PubMed]
27.
Williams JM, Pollock JS, Pollock DM: Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension 2004;44:770–775.
[PubMed]
28.
Tatchum-Talom R, Martin DS: Tempol improves vascular function in the mesenteric vascular bed of senescent rats. Can J Physiol Pharmacol 2004;82:200–207.
[PubMed]
29.
Sainz J, Wangensteen R, Rodríguez Gómez I, Moreno JM, Chamorro V, Osuna A, Bueno P, Vargas F: Antioxidant enzymes and effects of tempol on the development of hypertension induced by nitric oxide inhibition. Am J Hypertens 2005;18:871–877.
[PubMed]
30.
Bayorh MA, Mann G, Walton M, Eatman D: Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats. Clin Exp Hypertens 2006;28:121–132.
[PubMed]
31.
Asghar M, Lokhandwala MF: Antioxidant tempol lowers age-related increases in insulin resistance in Fischer 344 rats. Clin Exp Hypertens 2006;28:533–541.
[PubMed]
32.
Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T: Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007;50:877–883.
[PubMed]
33.
Hayden MR, Chowdhury NA, Cooper SA, Whaley-Connell A, Habibi J, Witte L, Wiedmeyer C, Manrique CM, Lastra G, Ferrario C, Stump C, Sowers JR: Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2007;292:F861–F867.
[PubMed]
34.
Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y: Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003;42:754–760.
[PubMed]
35.
Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND: Evolution of renal interstitial inflammation and NF-κB activation in spontaneously hypertensive rats. Am J Nephrol 2004;24:587–594.
[PubMed]
36.
Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND: Early and sustained inhibition of nuclear factor κB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005;315:51–57.
[PubMed]
37.
Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002;282:F191–F201.
[PubMed]
38.
Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann Biochem 1979;95:351–359.
39.
Nava M, Romero F, Quiroz V, Bonet L, Rodriguez-Iturbe B: Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol 2000;279:F910–F918.
[PubMed]
40.
Briggs RT, Robinson JM, Karnovsky ML, Karnovsky MJ: Superoxide production by polymorphonuclear leukocytes. A cytochemical approach. Histochemistry 1986;84:371–378.
[PubMed]
41.
Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B: Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002;283:F1132–F1141.
[PubMed]
42.
Rodriguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND: Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rats. Kidney Int 2005;68:1041–1047.
[PubMed]
43.
Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW: Intraglomerular platelet aggregation in experimental glomerulonephritis. Kidney Int 1990;37:1500–1508.
[PubMed]
44.
Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B: Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003;284:F447–F454.
[PubMed]
45.
Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, Ohnishi T, Sekimoto M, Tomita N, Shiozaki H, Monden M: Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem 1998;46:397–403.
[PubMed]
46.
Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, Reckelhoff JF, Granger JP: Role of reactive oxygen species in endothelin-induced hypertension. Hypertension 2003;42:806–810.
[PubMed]
47.
Marwaha A, Lokhandwala MF: Tempol reduces oxidative stress and restores renal dopamine D1-like receptor-G protein coupling and function in hyperglycemic rats. Am J Physiol Renal Physiol 2006;291:F58–F66.
[PubMed]
48.
Vaziri ND: Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001;8(4 suppl 1):S74–S79.
49.
Mitchell JB, Xavier S, DeLuca AM, Sowers AL, Cook JA, Krishna MC, Hahn SM, Russo A: A low-molecular-weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med 2003;34:93–102.
[PubMed]
50.
Kopkan L, Majid DS: Enhanced superoxide activity modulates renal function in NO- deficient hypertensive rats. Hypertension 2006;47:568–572.
[PubMed]
51.
Yanes L, Romero D, Iliescu R, Cucchiarelli VE, Fortepiani LA, Santacruz F, Bell W, Zhang H, Reckelhoff JF: Systemic arterial pressure response to two weeks of tempol therapy in SHR: involvement of NO, the RAS, and oxidative stress. Am J Physiol 2005;288:R903–R908.
[PubMed]
52.
Gonçalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, Zatz R: Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a non-steroidal anti-inflammatory. Am J Physiol Renal Physiol 2004;286:F945–F954.
[PubMed]
53.
Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008;294:F1–F9.
[PubMed]
54.
Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A: Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci USA 1992;89:5537–5541.
[PubMed]
55.
Vaz SM, Augusto O: Inhibition of myeloperoxidase-mediated protein nitration by tempol: kinetics, mechanism, and implications. Proc Natl Acad Sci USA 2008;105:8191–8196.
[PubMed]
56.
Roveri A, Coassin M, Maiorino M, Zamburlini A, van Amsterdam FT, Ratti E, Ursini F: Effect of hydrogen peroxide on calcium homeostasis in smooth muscle cells. Arch Biochem Biophys 1992;297:265–270.
[PubMed]
57.
Thakali K, Davenport L, Fink GD, Watts SW: Pleiotropic effects of hydrogen peroxide in arteries and veins from normotensive and hypertensive rats. Hypertension 2006;47:482–487.
[PubMed]
58.
Gao YJ, Lee RM: Hydrogen peroxide is an endothelium-dependent contracting factor in rat renal artery. Br J Pharmacol 2005;146:1061–1068.
[PubMed]
59.
Erdei N, Bagi Z, Edes I, Kaley G, Koller A: H2O2 increases production of constrictor prostaglandins in smooth muscle leading to enhanced arteriolar tone in type 2 diabetic mice. Am J Physiol 2007;292:H649–H656.
60.
Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ: New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1987;79:1379–1387.
[PubMed]
61.
Yoshioka T, Ichikawa I, Fogo A: Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 1991;2:902–912.
[PubMed]
62.
Vissers MC, Winterbourn CC: The effect of oxidants on neurtophil-mediated degradation of glomerular basement membrane collagen. Biochim Biophys Acta 1986;889:277–289.
[PubMed]
63.
Weiss SJ, Young J, LoBuglio AF, Slivka A, Nimeh NF: Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981;68:714–721.
[PubMed]
64.
Chen YF, Cowley AW Jr, Zou AP: Increased H2O2 counteracts the vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol 2003;285:R827–R833.
65.
Makino A, Skelton MM, Zou AP, Cowley AW Jr: Increased renal medullary H2O2 leads to hypertension. Hypertension 2003;42:25–30.
[PubMed]
66.
Kobayashi M, Sugiyama H, Wang DH, Toda N, Maeshima Y, Yamasaki Y, Masuoka N, Yamada M, Kira S, Makino H: Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int 2005;68:1018–1031.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
